PURPOSE: The use of recombinant human interleukin (rhIL)-15 as a potential therapeutic immune modulator and anticancer agent requires pure, stable preparations. However, purified rhIL-15 preparations readily accumulated heterogeneities. We sought to improve rhIL-15 stability through process, formulation, and targeted amino acid changes. METHODS: The solution state of rhIL-15 versus buffer composition and temperature was studied using SEC and IEX methods. rhIL-15 deamidation was confirmed using RP-HPLC/ESI-MS, enzymatic labeling, and peptide mapping. Deamidation kinetics were measured versus buffer composition and pH using RP-HPLC. Deamidation-resistant rhIL-15 variants (N77A, N77S, N77Q, G78A, and [N71S/N72A/N77A]) were produced in E. coli, then assayed for T-cell culture expansion potency and deamidation resistance. RESULTS: Adding 20% ethanol to buffers or heating at ≥32°C dispersed rhIL-15 transient pairs, improving purification efficiencies. Asparagine 77 deamidated rapidly at pH 7.4 with activation energy of 22.9 kcal per mol. Deamidation in citrate buffer was 17-fold slower at pH 5.9 than at pH 7.4. Amino acid substitutions at N77 or G78 slowed deamidation ≥23-fold. rhIL-15 variants N77A and (N71S/N72A/N77A) were active in a CTLL-2 proliferation assay equivalent to unsubstituted rhIL-15. CONCLUSIONS: The N77A and (N71S/N72A/N77A) rhIL-15 variants are resistant to deamidation and remain potent, thus providing enhanced drug substances for clinical evaluation.
PURPOSE: The use of recombinant human interleukin (rhIL)-15 as a potential therapeutic immune modulator and anticancer agent requires pure, stable preparations. However, purified rhIL-15 preparations readily accumulated heterogeneities. We sought to improve rhIL-15 stability through process, formulation, and targeted amino acid changes. METHODS: The solution state of rhIL-15 versus buffer composition and temperature was studied using SEC and IEX methods. rhIL-15 deamidation was confirmed using RP-HPLC/ESI-MS, enzymatic labeling, and peptide mapping. Deamidation kinetics were measured versus buffer composition and pH using RP-HPLC. Deamidation-resistant rhIL-15 variants (N77A, N77S, N77Q, G78A, and [N71S/N72A/N77A]) were produced in E. coli, then assayed for T-cell culture expansion potency and deamidation resistance. RESULTS: Adding 20% ethanol to buffers or heating at ≥32°C dispersed rhIL-15 transient pairs, improving purification efficiencies. Asparagine 77 deamidated rapidly at pH 7.4 with activation energy of 22.9 kcal per mol. Deamidation in citrate buffer was 17-fold slower at pH 5.9 than at pH 7.4. Amino acid substitutions at N77 or G78 slowed deamidation ≥23-fold. rhIL-15 variants N77A and (N71S/N72A/N77A) were active in a CTLL-2 proliferation assay equivalent to unsubstituted rhIL-15. CONCLUSIONS: The N77A and (N71S/N72A/N77A) rhIL-15 variants are resistant to deamidation and remain potent, thus providing enhanced drug substances for clinical evaluation.
Authors: L N Shanmugham; C Petrarca; S Frydas; J Donelan; M L Castellani; W Boucher; B Madhappan; S Tete'; K Falasca; P Conti; J Vecchiet Journal: J Exp Clin Cancer Res Date: 2006-12
Authors: K H Grabstein; J Eisenman; K Shanebeck; C Rauch; S Srinivasan; V Fung; C Beers; J Richardson; M A Schoenborn; M Ahdieh Journal: Science Date: 1994-05-13 Impact factor: 47.728
Authors: Andrea Hawe; Robert Poole; Stefan Romeijn; Piotr Kasper; Rob van der Heijden; Wim Jiskoot Journal: Pharm Res Date: 2009-04-03 Impact factor: 4.200
Authors: Vinay V Vyas; Dominic Esposito; Terry L Sumpter; Trevor L Broadt; James Hartley; George C Knapp; Wei Cheng; Man-Shiow Jiang; John M Roach; Xiaoyi Yang; Steven L Giardina; George Mitra; Jason L Yovandich; Stephen P Creekmore; Thomas A Waldmann; Jianwei Zhu Journal: Biotechnol Prog Date: 2011-12-09
Authors: M Thaysen-Andersen; E Chertova; C Bergamaschi; E S X Moh; O Chertov; J Roser; R Sowder; J Bear; J Lifson; N H Packer; B K Felber; G N Pavlakis Journal: Glycoconj J Date: 2015-11-12 Impact factor: 2.916
Authors: Wei Chen; Sigrid P Dubois; Anusara Daenthanasanmak; Thomas A Waldmann; Daniel V Santi; John A Hangasky; Jürgen R Müller; Ralph Reid Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751